Skip to content

Study on immunotherapy in patients with acute-on-chronic liver failure

Study on immunotherapy in patients with acute-on-chronic liver failure

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600127123
Enrollment
Unknown
Registered
2026-06-25
Start date
2025-10-28
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute-on-chronic liver failure with all etiologies

Interventions

Sponsors

The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Acute liver injury (ACLF) occurring on the basis of various chronic hepatitis, with the first test results at our hospital meeting the COSSH-ACLF diagnostic criteria: TB = 12mg/dL and INR = 1.5.

Exclusion criteria

Exclusion criteria: Any one of the following criteria requires exclusion: 1. Age 80 years; 2. Pregnancy; 3. Malignant tumors; 4. Severe chronic underlying diseases, such as chronic kidney insufficiency (uremia stage), chronic heart failure (grade III-IV), coronary heart disease patients taking anticoagulants after interventional surgery, severe sequelae from cerebral hemorrhage or infarction (such as lower limb paralysis or hemiplegia), myelofibrosis and aplastic anemia, acute exacerbation of chronic obstructive pulmonary disease, systemic complications arising from high blood pressure, thyroid diseases, etc.; 5. Received hormone and/or immunosuppressive treatment in the past month for non-liver diseases, such as using hormones for autoimmune diseases, anti-rejection drugs for organ transplants, etc.; 6. Severe mental illnesses, such as schizophrenia, depression, mania, etc.; 7. Contraindications for hormone therapy, such as gastrointestinal ulcers, severe infections, severe osteoporosis, uncontrolled hypertension, diabetes, etc.; 8. Others, such as HIV, syphilis, etc.

Design outcomes

Primary

MeasureTime frame
28/90 days survival status;

Secondary

MeasureTime frame
Liver function and other biochemical indicators;

Countries

China

Contacts

Public ContactJun Li

The FIrst Affiliated Hospital, College of Medicine, Zhejiang University

lijun2009@zju.edu.cn+86 571 8723 6625

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 3, 2026